Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01024335
Other study ID # #5962 DA027124
Secondary ID R01DA027124DPMC
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date January 2010
Est. completion date December 2012

Study information

Verified date May 2018
Source New York State Psychiatric Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to maintenance treatment with naltrexone in opioid-dependent individuals. We hypothesize that administering dronabinol during detoxification and during the first few weeks of naltrexone treatment will lead to improved naltrexone tolerability, resulting in better naltrexone compliance and treatment retention, and ultimately a reduction in opioid use and relapse rates.


Description:

The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to maintenance treatment with naltrexone in opioid-dependent individuals. We are proposing a randomized, double-blind, placebo controlled, parallel-groups, 8 week study of relapse prevention in opioid-dependent individuals. Participants will be randomized into one of two conditions (1) Naltrexone and Placebo (N=20) and (2) Naltrexone and dronabinol 15 mg bid (N=40). Treatment will be delivered in an outpatient setting except for the initial phase of inpatient detoxification, lasting 8 days. A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections), while dronabinol or placebo will be taken daily. In addition, patients will receive a psychosocial intervention that will include elements of motivational interviewing and cognitive-behavioral relapse prevention therapy. The primary aim is to test the efficacy of dronabinol in improving tolerability of naltrexone induction and reducing attrition during detoxification and the first two months of naltrexone treatment. The primary outcome will be the severity of opiate withdrawal and craving. The secondary outcome will be will be retention in treatment at study's end.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- 1. Adult, aged 18-60.

- 2. Meets Diagnostic and Statistical Manual -IV criteria for current opiate dependence disorder of at least six months duration, supported by a positive urine for opiates and a positive naloxone challenge test if the diagnosis is unclear.

- 3. Have a history of marijuana use (more than 30 occasions lifetime)

- 4. Voluntarily seeking treatment for opioid dependence

- 5. In otherwise good health based on complete medical history, physical examination, vital signs measurement, ECG, and laboratory tests (hematology, blood chemistry, urinalysis) within normal ranges.

- 6. Able to give informed consent.

Exclusion Criteria:

- 1. Physiologically dependent on alcohol or sedative-hypnotics with impending withdrawal.

- 2. Patients meeting current criteria for cannabis abuse or dependence, and those who used cannabis in the week prior to study entry as documented by the positive toxicology

- 3. Current Diagnostic and Statistical Manual -IV criteria of other substance use disorders. Exceptions include cannabis abuse or dependence, nicotine dependence, cocaine abuse or dependence, alcohol abuse or alcohol dependence without physiological dependence as long as opioid dependence is a primary disorder. Alcohol dependence with physiological dependence is exclusionary.

- 4. Significant current suicidal risk or 1 or more suicide attempts within the past year

- 5. History of accidental drug overdose in the last three years defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.

- 6. Positive serum pregnancy test, lactation, or unwillingness to use a satisfactory method of birth control

- 7. Active psychiatric disorder which might interfere with participation or make participation hazardous, including Diagnostic and Statistical Manual -IV organic mental disorder, psychotic disorder, or bipolar disorder with mania

- 8. History of allergic reaction, adverse reaction, or sensitivity to any study medication.

- 9. Acute hepatitis with serum glutamic-oxaloacetic transaminase or serum glutamic-pyruvic transaminase > 3 times the upper end of the laboratory normal range (chronic hepatitis is acceptable as we have found naltrexone treatment well tolerate and safe among patients with chronic hepatitis)

- 10. Currently prescribed or regularly taking opiates for chronic pain or medical illness.

- 11. Current participation in a methadone maintenance treatment program and/or regular use of illicit methadone (>30 mg per week).

- 12. Current participation in another intensive psychotherapy or substance abuse treatment program or participation in another treatment study.

- 13. Concurrent treatment with psychotropic medications

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
injectable naltrexone and dronabinol
Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
Naltrexone and placebo
Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.

Locations

Country Name City State
United States New York State Psychiatric Institute New York New York

Sponsors (2)

Lead Sponsor Collaborator
New York State Psychiatric Institute National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) . The Subjective Opiate Withdrawal Scale is a self-administered 16 scale containing 16 symptoms ranging in severity from 0 (not at all) to 4 (extremely). The SOWS total score is the sum of 16 items, ranging from 0 (no opiate withdrawal ) to 64 ( severe opiate withdrawal). Values from multiple assessments during the 8-week outpatient phase were averaged. 3x/week during 8 weeks of the trial or study participation
Primary Retention Of those participants randomized to the naltrexone and dronabinol arm, the number that completed all 8 weeks of treatment. retention over 8 weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02294253 - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone Phase 2/Phase 3
Completed NCT01592461 - Starting Treatment With Agonist Replacement Therapies Follow-up Study N/A
Terminated NCT00768482 - A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence Phase 3
Completed NCT01741350 - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users N/A
Terminated NCT04121546 - Collaborative Care for Opioid Dependence And Pain Pilot Study N/A
Withdrawn NCT03368794 - Naloxone to TReatment Entry in the Emergency Setting N/A
Completed NCT03447743 - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder Early Phase 1
Completed NCT04464421 - SMART Effectiveness Trial N/A
Recruiting NCT04189523 - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage N/A
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Recruiting NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification Phase 2
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Terminated NCT02935101 - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants Phase 2
Completed NCT01895270 - Improving Buprenorphine Detoxification Outcomes With Isradipine Phase 1/Phase 2
Completed NCT01717963 - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway Phase 3
Completed NCT01425060 - Improving Effective Contraceptive Use Among Opioid-maintained Women Phase 1
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4